Batch traceability is the ability to start from the lot identifier on a vial and reach, in writing, every record that describes that lot: where it came from, what it was tested for, what the results were, who released it, and where every unit went. A lot number that reaches none of that is a label, not a trace.
- Traceability is the reach of a lot identifier: from the label to the test report, the method, the laboratory, the release decision and every recipient.
- Synthesis, filling and distribution each define a lot boundary; a certificate usually describes the bulk and says nothing about fill mass.
- 21 CFR 211.188 and 211.194 list what a batch record and a laboratory record must contain; a certificate is a summary of that record, not a substitute.
- Records must outlive the lot: the pharmaceutical rule is at least one year past expiry, and the question that needs them is usually asked after use.
- Forward traceability, knowing every recipient of a lot, is what a recall depends on, and it requires the lot identifier to be stored against each order.
What a lot number is for
Every vial in a research peptide catalog carries a lot identifier, and most buyers read it the way they read a serial number, as a mark that the vial is one of a set. That is the least of what it does. A lot identifier is the key that joins a physical unit to a body of records, and traceability is the question of how much of that body the key actually reaches.
From a lot number on a label a buyer should be able to arrive at the analytical report for that lot, the date and method of each test, the laboratory that ran them, the release decision, and the distribution of every other unit from the same lot. If the number reaches all of that, the lot is traceable. If it reaches a marketing page and nothing else, it is decorative.
The standard against which this is worth measuring is the one written for pharmaceutical manufacturing, not because a research chemical supplier is a pharmaceutical manufacturer, which it is not, but because that is where the discipline of the batch record was worked out in full and where a laboratory buyer's expectations were formed. Title 21 of the Code of Federal Regulations, Part 211, sets out what a batch production and control record must contain, how long records are kept, and what a laboratory record has to hold. A research supplier that borrows the shape of those records, scaled to what it actually does, gives a buyer something to check. One that does not gives a buyer a number.
The architecture of a lot
A lot begins upstream of the supplier. Synthetic peptides are made in a synthesis run, purified, lyophilized in bulk, and then filled into vials, and each of those stages can define a batch boundary. The bulk lot is the quantity of purified, dried material from one synthesis and purification campaign. The fill lot is the set of vials filled from one bulk lot in one filling operation. A supplier that buys bulk and fills, or buys filled vials and labels, inherits lot boundaries from whoever performed the earlier stage, and a traceable record says which stage its lot identifier refers to and what upstream identifiers it maps to.
This matters because the analytical report almost always describes the bulk. Identity by mass spectrometry, purity by HPLC, and net peptide content are measured on a sample of the dried material before or during filling. A fill lot drawn from that bulk shares its identity and purity, but the fill introduces its own variables: the mass dispensed per vial, the seal, and the conditions the vials were held in afterward. A report that describes the bulk is honest evidence about what the vial contains; it is not evidence about how much, unless the fill weight was verified separately.
| Stage | Defines | Record typically establishes | Does not establish |
|---|---|---|---|
| Synthesis and purification | Bulk lot | Identity, purity, impurity profile, net content of the dried material | Fill mass, seal integrity, storage history of vials |
| Filling | Fill lot | Which bulk lot, fill date, target and verified fill mass, container and closure | Purity, unless re-tested after filling |
| Labelling and distribution | Distribution lot | Which fill lot, label content, ship dates and recipients | Anything analytical |
A single lot identifier on a vial should resolve to a chain that names each of those stages, or should say plainly that the supplier's record begins at the fill and the bulk data is the manufacturer's. Either is defensible. Silence about which one applies is not.
What the batch record has to contain
The regulation for drug manufacturers, 21 CFR 211.188, lists what a batch production and control record must document: the identity of the components used and their quantities, the equipment used, the in-process and laboratory control results, the labelling used, a description of the containers and closures, the dates of each step, and the identity of the people who performed and checked them. Section 211.194 adds the requirements for the laboratory record itself: a description of the sample, the method used and its reference, the weights and measures taken, the calculations, the results, and the signatures of the analyst and the reviewer, with the raw data retained.
Read those two lists against a typical research peptide certificate and the gap is obvious. The certificate states a purity percentage and a mass; the batch record behind it would state the column, the gradient, the detection wavelength, the injection volume, the sample preparation, the integration parameters, and who reviewed the chromatogram. A certificate is a summary. The record is the evidence. A supplier does not have to publish the full record for every lot, and a research buyer rarely needs it, but a supplier should be able to produce it for a given lot on request, and a buyer with a discrepancy to resolve is entitled to ask.
Section 211.165 closes the loop between the record and the decision to sell. It requires that a batch be shown, by laboratory determination, to conform to its specifications before release, and that a batch failing them be rejected. The consequence for a certificate is that a result on its own is not a release decision; the specification has to sit beside it. A purity of 97.2 percent is a pass against a specification of 95 and a failure against one of 98, and a certificate that prints the number without the limit has left the reader to guess which.
The same section of the regulation is why a certificate without a method reference is a weak document. A purity of 98.6 percent means one thing measured by reversed-phase HPLC at 214 nanometres and something else measured at 280, and nothing at all if the method is not stated. The purity testing guide covers what each method sees; the traceability point is simply that a record which does not name its method cannot be repeated, and a result that cannot be repeated cannot be disputed either.
Retention, and why a report has a date on it
Section 211.180 sets the retention rule for drug batch records: at least one year past the expiration date of the batch, and for products with no expiry, a fixed period after distribution. The principle carries over cleanly. A lot's records need to outlive the lot, because the question that needs them is usually asked after the material has been used, when a result was unexpected and the laboratory wants to know whether the reagent was what it was supposed to be. A supplier that discards or overwrites lot records when a lot sells out has removed the only evidence that could answer that question.
Retention also determines whether a retest can mean anything. Section 211.166 requires a written stability programme for drug products, with the samples, intervals and methods stated, and section 211.170 requires reserve samples to be kept. A research supplier will not run a formal stability programme on every lot, but it can state a retest date on the certificate, keep the report from the original test, and keep a reserve vial. Those three things are what let a supplier answer, a year on, whether a lot still meets its release figures or whether the buyer's unexpected result had a cause on the shelf.
The date on a certificate is part of the record for the same reason. A purity measured at release describes the material at release. A lyophilized peptide in a sealed vial degrades slowly, but it degrades, and a report that carries its test date lets a buyer judge how much time has passed. A report without one is a photograph with no timestamp. The lyophilized storage guide sets out what happens over that time and why the seal matters more than the refrigerator.
Where every unit went
Traceability runs in both directions. Forward traceability is the ability to start from a lot and list every recipient of every unit; backward traceability is the ability to start from a vial in a laboratory and reach the lot's records. Both depend on the same thing: the lot identifier being captured at the point of sale and stored against the order. A supplier whose order system records only a SKU has forward traceability at the level of product, which is to say none at the level of lot. If a lot turns out to be wrong, that supplier cannot say who has it.
This is the capability a recall depends on. 21 CFR Part 7, Subpart C, describes the recall process the FDA expects of firms: a recall strategy stating the depth of the recall, the means of notifying consignees, and the effectiveness checks that confirm the notification reached them. The FDA classifies recalls by the seriousness of the hazard, from Class I for situations that can cause serious harm down to Class III for products unlikely to cause harm at all. None of that machinery applies as regulation to a research chemical supplier. All of it applies as a test of whether the supplier's records could support a recall if one were ever needed, and a supplier that cannot name the recipients of a lot fails the test before it starts.
The practical form of forward traceability at a research supplier is unglamorous: the lot identifier printed on the packing record that ships with the order, the same identifier stored against the order in the supplier's system, and a way to query by lot. The packing record matters more than it looks, because it is the copy the buyer holds. A parcel that arrives with a record listing SKU, size and lot for every vial can be reconciled against the order and against the product records without a conversation, and reconciled again months later when the question finally comes up.
Reading a supplier's traceability from outside
A buyer cannot audit a supplier's record system, but a buyer can test its edges, and the edges tell most of the story. Five questions, all answerable from a product page, a certificate and one email, sort suppliers quickly.
- Does the product record name the lot currently shipping? A record that names a lot has a record system behind it. One that names none, or names a lot that was tested three years ago, does not.
- Does the certificate carry a lot identifier, a test date, a method reference, and an issuing laboratory? Those four fields are the minimum that make a certificate a record rather than a statement.
- Can the issuing laboratory confirm the report? The Verify a COA page explains how to check a certificate at its source. A supplier whose laboratory cannot be named or reached has broken the chain at the first link.
- Does the parcel arrive with a packing record listing the lot of every vial? If not, the supplier does not know which lot you received either.
- Ask support which lot a past order shipped from. A supplier with forward traceability answers from its records in a sentence. One without it asks you to check the vial.
None of these questions is hostile. A supplier that keeps records will answer them readily, because the answers are the reason it keeps them. A supplier that treats them as an imposition has told you how it would behave when a real problem arose, which is the only time traceability is worth anything.
How lot records are kept here
Each LabFirst product record carries the lot identifier of the vials currently shipping and, where the analytical report for that lot has landed, the certificate and the issuing laboratory's own verification route. Fields not yet verified are shown as pending rather than filled from a supplier sheet, because a pending field is honest and a copied one is a claim nobody checked. Every parcel ships with a packing record listing the SKU, size and lot of each vial, and the same lot identifier is stored against the order so a past shipment can be traced by lot on request. The compliance page sets out what LabFirst is and is not; the shipping page describes the packing record and the reconciliation it is meant to allow.
Traceability describes where material came from and where it went. It is not a statement about what the material is for. FOR LABORATORY AND IN-VITRO RESEARCH USE ONLY. NOT FOR HUMAN OR ANIMAL CONSUMPTION. Lot records exist so that a laboratory can confirm what it received and so that a problem with a lot can be found and contained, and for no other reason.
Common questions
What should a peptide lot number let me find?
Is a bulk-lot certificate valid for the vial I received?
Do 21 CFR Part 211 batch-record rules apply to research peptide suppliers?
How long should a supplier keep lot records?
What is the simplest test of a supplier's traceability?
Sources
- 21 CFR 211.188, Batch production and control records. The regulatory list of what a batch record must document, used here as the fullest written model of a traceable lot record.
- 21 CFR 211.194, Laboratory records. What a laboratory record must hold: sample description, method reference, measurements, calculations, results and signatures. The reason a certificate without a method is a weak document.
- 21 CFR 211.180, General requirements (records and reports). Retention periods for batch records; the principle that records must outlive the lot.
- 21 CFR 211.166, Stability testing. The written stability programme requirement, cited for why a retest date needs an original report and a reserve sample behind it.
- 21 CFR 211.165, Testing and release for distribution. Release requires laboratory determination of conformance to specifications, and a failing batch is rejected; the reason a certificate should print the limit beside the result.
- 21 CFR 211.84, Testing and approval or rejection of components. The conditions under which a manufacturer may rely on a supplier's certificate, which frame what a certificate is expected to carry.
- 21 CFR Part 7, Subpart C, Recalls (including product corrections). The recall process the FDA expects: strategy, depth, consignee notification and effectiveness checks, all of which depend on forward traceability.
- FDA, Recalls: Background and Definitions. The Class I, II and III definitions referred to in the text.